Hospital
Fairfield Medical Center
Fairfield Medical Center was paid $38.76M by Medicaid between Jan 2018 and Dec 2024, across 431 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoFAIRFIELD MEDICAL CENTER
LANCASTER, OH 43130
LANCASTER, OH 43130
33aNPI1467433763assigned 11/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.76M
24GClaims1,104,295
24DCodes billed431
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#29 of 101
Median peer was paid$22.32M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,185 | $3.19M | |
| 2019 | 97,369 | $2.85M | |
| 2020 | 80,727 | $3.21M | |
| 2021 | 98,732 | $3.75M | |
| 2022 | 114,284 | $4.23M | |
| 2023 | 351,008 | $12.77M | |
| 2024incomplete | 253,990 | $8.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 53,898 | 49,122 | $6.21M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 43,471 | 38,291 | $5.31M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 17,388 | 14,335 | $4.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 19,732 | 17,252 | $2.51M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 15,582 | 14,340 | $1.53M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 5,708 | 4,886 | $1.45M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 4,875 | 4,306 | $1.05M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 13,119 | 3,718 | $917K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 5,339 | 3,837 | $693K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.6% | 78 | 50 | $611K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 3,443 | 2,507 | $610K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,087 | 954 | $493K |
419 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 67,192 | $482K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 5,534 | $448K |
| G0378 | Hospital observation service, per hour | 1.1% | 7,534 | $443K |
| 80053 | Comprehensive metabolic panel | 1.1% | 19,519 | $421K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 2,241 | $409K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,557 | $384K |
| 59025 | Fetal non-stress test | <1% | 2,649 | $375K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,168 | $355K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,652 | $337K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,591 | $332K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,310 | $327K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,884 | $317K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,463 | $315K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 205 | $288K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 78,641 | $200K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,652 | $193K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,661 | $178K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,389 | $175K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 331 | $166K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,071 | $160K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,493 | $151K |
| 70496 | <1% | 649 | $141K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,425 | $140K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 237 | $128K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,620 | $127K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,894 | $120K |
| 80061 | Lipid panel | <1% | 9,661 | $111K |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,371 | $109K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 222 | $109K |
| 80076 | <1% | 27,746 | $106K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,137 | $105K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,060 | $101K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,000 | $97K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 571 | $95K |
| 95811 | <1% | 170 | $95K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 426 | $92K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,838 | $92K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,660 | $91K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,249 | $91K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 345 | $90K |
| 71271 | <1% | 553 | $90K | |
| 84439 | <1% | 5,046 | $87K | |
| 97161 | <1% | 1,878 | $85K | |
| 71250 | <1% | 1,140 | $84K | |
| 95806 | <1% | 229 | $83K | |
| 96367 | <1% | 1,121 | $80K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,015 | $73K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 352 | $69K |
| 97113 | <1% | 974 | $67K | |
| 93458 | <1% | 115 | $67K | |
| 85027 | <1% | 9,196 | $66K | |
| 84484 | <1% | 19,248 | $66K | |
| 82607 | <1% | 3,272 | $64K | |
| 87070 | <1% | 6,421 | $64K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 450 | $63K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,069 | $60K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,736 | $60K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 119 | $58K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,192 | $57K |
| 94060 | <1% | 706 | $55K | |
| 76642 | <1% | 472 | $54K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 392 | $54K |
| 12001 | <1% | 322 | $52K | |
| 47562 | <1% | 22 | $47K | |
| 93971 | <1% | 647 | $46K | |
| 83735 | <1% | 19,677 | $42K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 153 | $41K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 80 | $39K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,033 | $39K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 618 | $39K |
| 73030 | <1% | 1,261 | $37K | |
| 94618 | <1% | 449 | $37K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,135 | $36K |
| 82728 | <1% | 2,136 | $34K | |
| 93798 | <1% | 624 | $34K | |
| 73130 | <1% | 1,141 | $34K | |
| 97803 | <1% | 404 | $32K | |
| 86803 | <1% | 1,449 | $31K | |
| 27447 | <1% | 13 | $31K | |
| 76536 | <1% | 289 | $29K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,433 | $29K |
| 93970 | <1% | 235 | $29K | |
| 83540 | <1% | 2,953 | $28K | |
| 73630 | <1% | 1,253 | $27K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 218 | $27K |
| 73221 | <1% | 152 | $27K | |
| 73560 | <1% | 1,215 | $27K | |
| 72100 | <1% | 730 | $27K | |
| 74018 | <1% | 953 | $26K | |
| 93922 | <1% | 428 | $26K | |
| 43235 | <1% | 58 | $25K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,171 | $24K |
| 73564 | <1% | 369 | $24K | |
| 93017 | <1% | 322 | $23K | |
| 73110 | <1% | 952 | $22K | |
| 73610 | <1% | 1,182 | $22K | |
| 94729 | <1% | 710 | $22K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 713 | $21K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 492 | $21K |
| 87077 | <1% | 3,367 | $21K | |
| 76830 | Ultrasound, transvaginal | <1% | 585 | $21K |
| 86038 | <1% | 788 | $20K | |
| 72131 | <1% | 620 | $20K | |
| 97165 | <1% | 434 | $20K | |
| 85610 | <1% | 6,068 | $20K | |
| 93880 | <1% | 264 | $20K | |
| 86850 | <1% | 1,218 | $20K | |
| 83550 | <1% | 2,348 | $20K | |
| 82746 | <1% | 2,054 | $20K | |
| 36592 | <1% | 762 | $19K | |
| 94726 | <1% | 564 | $19K | |
| 73502 | <1% | 711 | $19K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 140 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 962 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,190 | $18K |
| 83970 | <1% | 713 | $18K | |
| 52000 | <1% | 39 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,827 | $18K |
| J3490 | Unclassified drugs | <1% | 2,733 | $18K |
| 70486 | <1% | 308 | $17K | |
| 97116 | <1% | 812 | $17K | |
| 82805 | <1% | 611 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 192 | $17K |
| 82570 | <1% | 1,960 | $16K | |
| 97162 | <1% | 337 | $16K | |
| 74174 | <1% | 297 | $16K | |
| 80069 | <1% | 999 | $16K | |
| 84702 | <1% | 1,221 | $15K | |
| 75574 | <1% | 60 | $15K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,202 | $14K |
| 80081 | <1% | 483 | $14K | |
| 70498 | <1% | 593 | $14K | |
| 72114 | <1% | 271 | $14K | |
| 86140 | <1% | 1,279 | $14K | |
| 93242 | <1% | 210 | $12K | |
| 84153 | <1% | 955 | $12K | |
| 27096 | <1% | 26 | $12K | |
| 86900 | <1% | 1,342 | $12K | |
| 87340 | <1% | 632 | $12K | |
| 73562 | <1% | 442 | $12K | |
| 97166 | <1% | 89 | $11K | |
| 70491 | <1% | 36 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 637 | $11K |
| 81015 | <1% | 22,080 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,581 | $11K |
| 12011 | <1% | 62 | $11K | |
| 73080 | <1% | 478 | $11K | |
| 87081 | <1% | 704 | $10K | |
| 80320 | <1% | 606 | $10K | |
| 36902 | <1% | 13 | $10K | |
| 78264 | <1% | 34 | $9K | |
| 84403 | <1% | 587 | $9K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 10,554 | $9K |
| 29580 | <1% | 55 | $9K | |
| 72052 | <1% | 137 | $9K | |
| 72040 | <1% | 189 | $8K | |
| 87186 | <1% | 2,291 | $8K | |
| 83690 | <1% | 17,796 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,462 | $8K |
| 86317 | <1% | 247 | $8K | |
| 82784 | <1% | 621 | $8K | |
| 84402 | <1% | 373 | $8K | |
| 82565 | <1% | 1,002 | $8K | |
| 72128 | <1% | 410 | $8K | |
| 73140 | <1% | 278 | $8K | |
| 90715 | <1% | 521 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,124 | $7K |
| 81003 | <1% | 13,149 | $7K | |
| 82330 | <1% | 532 | $7K | |
| 84550 | <1% | 1,180 | $7K | |
| 82043 | <1% | 1,246 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,331 | $7K |
| 86592 | <1% | 563 | $7K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 76 | $7K |
| 93296 | <1% | 482 | $7K | |
| 84450 | <1% | 628 | $7K | |
| 80074 | <1% | 397 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,167 | $6K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 513 | $6K |
| 72072 | <1% | 166 | $6K | |
| 86431 | <1% | 387 | $6K | |
| 29581 | <1% | 40 | $6K | |
| 76775 | <1% | 82 | $6K | |
| 72141 | <1% | 40 | $6K | |
| 82948 | <1% | 5,676 | $6K | |
| 82150 | <1% | 631 | $6K | |
| 73590 | <1% | 336 | $6K | |
| 82950 | <1% | 391 | $6K | |
| 97802 | <1% | 56 | $5K | |
| 93225 | <1% | 43 | $5K | |
| 84460 | <1% | 765 | $5K | |
| 85652 | <1% | 1,333 | $5K | |
| 93298 | <1% | 752 | $5K | |
| 97016 | <1% | 240 | $5K | |
| 92523 | <1% | 61 | $5K | |
| 86364 | <1% | 253 | $5K | |
| 73522 | <1% | 129 | $5K | |
| 83880 | <1% | 1,613 | $4K | |
| 81025 | <1% | 13,636 | $4K | |
| 96376 | <1% | 2,918 | $4K | |
| 76870 | <1% | 45 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 305 | $4K |
| 97533 | <1% | 66 | $4K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 211 | $4K |
| 72050 | <1% | 64 | $4K | |
| 10060 | <1% | 27 | $4K | |
| 87205 | <1% | 974 | $4K | |
| 82105 | <1% | 233 | $4K | |
| 84425 | <1% | 316 | $4K | |
| 84436 | <1% | 1,300 | $4K | |
| 77062 | <1% | 111 | $4K | |
| 84156 | <1% | 863 | $3K | |
| 82248 | <1% | 359 | $3K | |
| 85018 | <1% | 1,501 | $3K | |
| 86480 | <1% | 71 | $3K | |
| 78227 | <1% | 16 | $3K | |
| 81596 | <1% | 23 | $3K | |
| 85014 | <1% | 810 | $3K | |
| 00840 | <1% | 113 | $3K | |
| 83921 | <1% | 322 | $3K | |
| 72110 | <1% | 60 | $3K | |
| 76937 | <1% | 216 | $3K | |
| 82550 | <1% | 743 | $3K | |
| 85730 | <1% | 3,116 | $3K | |
| 88142 | <1% | 170 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 211 | $3K |
| 77334 | <1% | 15 | $3K | |
| 93246 | <1% | 42 | $3K | |
| 77080 | <1% | 39 | $3K | |
| 86708 | <1% | 138 | $3K | |
| 73620 | <1% | 59 | $3K | |
| 77336 | <1% | 22 | $2K | |
| 88307 | <1% | 19 | $2K | |
| 00731 | <1% | 608 | $2K | |
| 86231 | <1% | 110 | $2K | |
| 85009 | <1% | 590 | $2K | |
| 86704 | <1% | 116 | $2K | |
| 84100 | <1% | 905 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 25,504 | $2K |
| 83615 | <1% | 422 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,362 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 20 | $2K |
| 86200 | <1% | 106 | $2K | |
| 97012 | <1% | 69 | $2K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 317 | $2K |
| 73090 | <1% | 209 | $2K | |
| 84590 | <1% | 150 | $2K | |
| 84207 | <1% | 150 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 671 | $2K |
| 82077 | <1% | 2,814 | $2K | |
| 83655 | <1% | 71 | $2K | |
| 87486 | <1% | 218 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 126 | $2K |
| 87517 | <1% | 23 | $1K | |
| 83001 | <1% | 74 | $1K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 886 | $1K |
| 86003 | <1% | 57 | $1K | |
| 84703 | <1% | 454 | $1K | |
| 87040 | <1% | 1,547 | $1K | |
| 83525 | <1% | 53 | $1K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 275 | $1K |
| 86901 | <1% | 1,275 | $1K | |
| 83605 | <1% | 2,236 | $1K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 13 | $1K |
| 84481 | <1% | 79 | $1K | |
| 88304 | <1% | 572 | $1K | |
| 88112 | <1% | 30 | $1K | |
| 80329 | <1% | 102 | $1K | |
| 88342 | <1% | 247 | $995.54 | |
| 84146 | <1% | 38 | $969.08 | |
| 88341 | <1% | 30 | $911.23 | |
| 71100 | <1% | 95 | $893.03 | |
| 80348 | <1% | 43 | $875.97 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 686 | $851.35 |
| 85379 | <1% | 985 | $840.61 | |
| 84112 | <1% | 46 | $807.05 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,538 | $789.81 |
| 82947 | <1% | 154 | $778.45 | |
| J1815 | Injection, insulin, per 5 units | <1% | 449 | $763.39 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,034 | $730.46 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,048 | $725.40 |
| 72192 | <1% | 28 | $692.84 | |
| 80143 | <1% | 1,618 | $680.19 | |
| 82375 | <1% | 614 | $670.22 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 62 | $657.86 |
| 86235 | <1% | 39 | $647.57 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 289 | $621.06 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,821 | $607.36 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,428 | $577.60 |
| 87147 | <1% | 200 | $574.90 | |
| 86762 | <1% | 41 | $563.82 | |
| 86707 | <1% | 24 | $542.97 | |
| 93299 | <1% | 36 | $540.43 | |
| 84132 | <1% | 475 | $535.08 | |
| 86334 | <1% | 18 | $514.44 | |
| 87581 | <1% | 219 | $506.21 | |
| 93926 | <1% | 15 | $489.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,038 | $487.86 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,379 | $479.83 |
| 83993 | <1% | 30 | $473.85 | |
| 87807 | <1% | 728 | $471.72 | |
| 80354 | <1% | 60 | $470.15 | |
| J1335 | Injection, ertapenem sodium, 500 mg | <1% | 27 | $466.64 |
| 72070 | <1% | 13 | $448.86 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,354 | $440.06 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,578 | $425.08 |
| 80362 | <1% | 34 | $419.18 | |
| 96368 | <1% | 335 | $417.70 | |
| 84155 | <1% | 50 | $399.09 | |
| 84165 | <1% | 33 | $396.76 | |
| 80179 | <1% | 1,611 | $375.72 | |
| 84144 | <1% | 12 | $374.70 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,191 | $372.30 |
| 80324 | <1% | 18 | $371.40 | |
| 72202 | <1% | 15 | $344.56 | |
| 82140 | <1% | 273 | $341.54 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 29 | $335.76 |
| 83050 | <1% | 610 | $330.24 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 8,376 | $329.07 |
| 87350 | <1% | 22 | $323.35 | |
| 80361 | <1% | 33 | $312.36 | |
| 87210 | <1% | 637 | $300.16 | |
| 84134 | <1% | 34 | $285.96 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 356 | $279.01 |
| 83002 | <1% | 25 | $277.30 | |
| 87324 | <1% | 15 | $248.94 | |
| C1769 | Guide wire | <1% | 1,000 | $244.17 |
| 77061 | <1% | 18 | $240.54 | |
| 80365 | <1% | 31 | $240.18 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 791 | $238.73 |
| 84520 | <1% | 54 | $233.34 | |
| 86376 | <1% | 13 | $227.26 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 585 | $226.37 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 889 | $221.00 |
| 86706 | <1% | 16 | $198.93 | |
| 80353 | <1% | 17 | $185.70 | |
| 80349 | <1% | 15 | $185.25 | |
| 81001 | <1% | 1,757 | $176.20 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 1,559 | $169.19 |
| 85045 | <1% | 30 | $160.19 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 869 | $153.70 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 24 | $142.14 |
| 87449 | <1% | 15 | $141.41 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,446 | $140.04 |
| 86160 | <1% | 12 | $136.32 | |
| 84145 | <1% | 35 | $131.76 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,110 | $127.87 |
| 86618 | <1% | 15 | $123.18 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,759 | $116.99 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 804 | $99.52 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,463 | $91.47 |
| 82010 | <1% | 164 | $87.99 | |
| 93288 | <1% | 15 | $85.07 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 596 | $84.73 |
| A9270 | Non-covered item or service | <1% | 1,110 | $84.07 |
| 29125 | <1% | 181 | $69.62 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,188 | $69.47 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,167 | $69.26 |
| 94760 | <1% | 996 | $62.90 | |
| 80164 | <1% | 13 | $62.46 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 141 | $62.03 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,584 | $61.12 |
| 82977 | <1% | 16 | $54.93 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 758 | $54.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 394 | $49.19 |
| 86308 | <1% | 30 | $42.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 505 | $40.21 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 199 | $36.65 |
| 73552 | <1% | 15 | $35.35 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 516 | $34.72 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 141 | $34.41 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 637 | $31.50 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 252 | $29.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,020 | $27.75 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 917 | $27.47 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 576 | $25.77 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 79 | $23.75 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,209 | $23.01 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 221 | $22.86 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,119 | $22.70 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 39 | $21.15 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 470 | $15.82 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 97 | $13.51 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 189 | $11.87 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 430 | $11.73 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 145 | $9.77 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 229 | $9.69 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 80 | $8.84 |
| 85347 | <1% | 27 | $8.31 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 39 | $8.05 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 338 | $5.90 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 89 | $3.33 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 242 | $3.13 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 124 | $2.67 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 514 | $2.04 |
| 99152 | 0% | 544 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 2,244 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 754 | $0.00 |
| 00811 | 0% | 378 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 135 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 263 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 130 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 48 | $0.00 |
| 01844 | 0% | 17 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 49 | $0.00 |
| 01402 | 0% | 27 | $0.00 | |
| 76942 | 0% | 14 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 18 | $0.00 |
| 96417 | 0% | 31 | $0.00 | |
| 29515 | 0% | 13 | $0.00 | |
| 00126 | 0% | 80 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 66 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 157 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 172 | $0.00 |
| 00790 | 0% | 98 | $0.00 | |
| 91035 | 0% | 16 | $0.00 | |
| 76998 | 0% | 14 | $0.00 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 19 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJANOSO, JOHN (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Fairfield Healthcare Professionals INC | Lancaster, OH | $6.64M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.